Display options
Cite
Kretz AL, Trauzold A, Hillenbrand A, et al. TRAILblazing Strategies for Cancer Treatment. Cancers (Basel). 2019;11(4)doi: 10.3390/cancers11040456.
Kretz, A. L., Trauzold, A., Hillenbrand, A., Knippschild, U., Henne-Bruns, D., von Karstedt, S., & Lemke, J. (2019). TRAILblazing Strategies for Cancer Treatment. Cancers, 11(4), . https://doi.org/10.3390/cancers11040456
Kretz, Anna-Laura, et al. "TRAILblazing Strategies for Cancer Treatment." Cancers vol. 11,4 (2019). doi: https://doi.org/10.3390/cancers11040456
Kretz AL, Trauzold A, Hillenbrand A, Knippschild U, Henne-Bruns D, von Karstedt S, Lemke J. TRAILblazing Strategies for Cancer Treatment. Cancers (Basel). 2019 Mar 30;11(4). doi: 10.3390/cancers11040456. PMID: 30935038; PMCID: PMC6521007.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Mar 30;11(4). doi: 10.3390/cancers11040456.

TRAILblazing Strategies for Cancer Treatment.

Cancers

Anna-Laura Kretz, Anna Trauzold, Andreas Hillenbrand, Uwe Knippschild, Doris Henne-Bruns, Silvia von Karstedt, Johannes Lemke

Affiliations

  1. Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany. [email protected].
  2. Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany. [email protected].
  3. Clinic for General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. [email protected].
  4. Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany. [email protected].
  5. Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany. [email protected].
  6. Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany. [email protected].
  7. Department of Translational Genomics, University Hospital Cologne, Weyertal 115b, 50931 Cologne, Germany. [email protected].
  8. Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann Straße 26, 50931 Cologne, Germany. [email protected].
  9. Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany. [email protected].

PMID: 30935038 PMCID: PMC6521007 DOI: 10.3390/cancers11040456

Abstract

In the late 1990s, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF-family, started receiving much attention for its potential in cancer therapy, due to its capacity to induce apoptosis selectively in tumour cells in vivo. TRAIL binds to its membrane-bound death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) inducing the formation of a death-inducing signalling complex (DISC) thereby activating the apoptotic cascade. The ability of TRAIL to also induce apoptosis independently of p53 makes TRAIL a promising anticancer agent, especially in p53-mutated tumour entities. Thus, several so-called TRAIL receptor agonists (TRAs) were developed. Unfortunately, clinical testing of these TRAs did not reveal any significant anticancer activity, presumably due to inherent or acquired TRAIL resistance of most primary tumour cells. Since the potential power of TRAIL-based therapies still lies in TRAIL's explicit cancer cell-selectivity, a desirable approach going forward for TRAIL-based cancer therapy is the identification of substances that sensitise tumour cells for TRAIL-induced apoptosis while sparing normal cells. Numerous of such TRAIL-sensitising strategies have been identified within the last decades. However, many of these approaches have not been verified in animal models, and therefore potential toxicity of these approaches has not been taken into consideration. Here, we critically summarise and discuss the status quo of TRAIL signalling in cancer cells and strategies to force tumour cells into undergoing apoptosis triggered by TRAIL as a cancer therapeutic approach. Moreover, we provide an overview and outlook on innovative and promising future TRAIL-based therapeutic strategies.

Keywords: TRAIL in cancer; TRAIL sensitising; TRAIL signalling; TRAIL-induced apoptosis

References

  1. Cell Mol Life Sci. 1999 Jan;55(1):64-75 - PubMed
  2. Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55 - PubMed
  3. Cell Death Differ. 1998 Apr;5(4):271-88 - PubMed
  4. Cancer Res. 1999 Jun 15;59(12):2770-5 - PubMed
  5. J Clin Invest. 1999 Jul;104(2):155-62 - PubMed
  6. Blood. 1999 Sep 1;94(5):1727-37 - PubMed
  7. Genes Dev. 1999 Oct 1;13(19):2514-26 - PubMed
  8. Nat Struct Biol. 1999 Nov;6(11):1048-53 - PubMed
  9. Mol Cell. 1999 Oct;4(4):563-71 - PubMed
  10. Nature. 1999 Dec 9;402(6762):672-6 - PubMed
  11. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  12. Biochemistry. 2000 Feb 1;39(4):633-40 - PubMed
  13. J Biol Chem. 2000 Jul 7;275(27):20632-7 - PubMed
  14. J Biol Chem. 2000 Jul 28;275(30):23319-25 - PubMed
  15. Nat Cell Biol. 2000 Apr;2(4):241-3 - PubMed
  16. Nat Med. 2000 May;6(5):502-3 - PubMed
  17. Nat Med. 2000 May;6(5):564-7 - PubMed
  18. J Biol Chem. 2000 Aug 18;275(33):25065-8 - PubMed
  19. Immunity. 2000 Jun;12(6):599-609 - PubMed
  20. Immunity. 2000 Jun;12(6):611-20 - PubMed
  21. Breast Cancer Res Treat. 2000 May;61(1):87-96 - PubMed
  22. Neoplasia. 1999 Aug;1(3):197-207 - PubMed
  23. Oncogene. 2000 Aug 24;19(36):4174-7 - PubMed
  24. FEBS Lett. 2000 Oct 6;482(3):193-9 - PubMed
  25. Nature. 2000 Oct 12;407(6805):770-6 - PubMed
  26. Med Pediatr Oncol. 2000 Dec;35(6):608-11 - PubMed
  27. Oncogene. 2000 Nov 16;19(48):5477-86 - PubMed
  28. J Biol Chem. 2001 Apr 13;276(15):11615-23 - PubMed
  29. Breast Cancer Res Treat. 2000 Nov;64(2):211-9 - PubMed
  30. Cancer Res. 2001 Feb 1;61(3):1138-43 - PubMed
  31. EMBO J. 2001 Mar 1;20(5):998-1009 - PubMed
  32. Cancer Res. 2001 Feb 15;61(4):1314-9 - PubMed
  33. J Biol Chem. 2001 May 11;276(19):16484-90 - PubMed
  34. J Biol Chem. 2001 Jun 8;276(23):20633-40 - PubMed
  35. Nat Med. 2001 Apr;7(4):383-5 - PubMed
  36. Oncogene. 2001 Jan 18;20(3):399-403 - PubMed
  37. Clin Cancer Res. 2001 Jun;7(6):1688-97 - PubMed
  38. Cancer Res. 2001 Jul 1;61(13):4942-6 - PubMed
  39. Nat Rev Mol Cell Biol. 2001 Jul;2(7):550-6 - PubMed
  40. Mol Cell. 2001 Mar;7(3):683-94 - PubMed
  41. Mol Cell Biol. 2001 Aug;21(16):5299-305 - PubMed
  42. Oncogene. 2001 Jul 12;20(31):4258-69 - PubMed
  43. J Biol Chem. 2001 Dec 7;276(49):46639-46 - PubMed
  44. Cancer Res. 2001 Oct 1;61(19):7339-48 - PubMed
  45. Leukemia. 2001 Dec;15(12):1868-77 - PubMed
  46. Genes Dev. 2002 Jan 1;16(1):33-45 - PubMed
  47. Nat Med. 2002 Mar;8(3):274-81 - PubMed
  48. Oncogene. 2002 Apr 4;21(15):2283-94 - PubMed
  49. Nat Med. 2002 Aug;8(8):808-15 - PubMed
  50. Nat Rev Cancer. 2002 Jun;2(6):420-30 - PubMed
  51. EMBO J. 2002 Sep 2;21(17):4520-30 - PubMed
  52. J Biol Chem. 2002 Nov 22;277(47):45162-71 - PubMed
  53. Neoplasia. 2002 Nov-Dec;4(6):551-7 - PubMed
  54. Prostate. 2002 Dec 1;53(4):286-99 - PubMed
  55. Mol Cancer Ther. 2002 Oct;1(12):1051-8 - PubMed
  56. Cell Death Differ. 2003 Jan;10(1):66-75 - PubMed
  57. Cancer Res. 2003 Apr 1;63(7):1712-21 - PubMed
  58. Oncogene. 2003 May 15;22(19):2869-81 - PubMed
  59. N Engl J Med. 2003 Jun 26;348(26):2609-17 - PubMed
  60. Oncogene. 2003 Jul 3;22(27):4266-80 - PubMed
  61. Cell. 2003 Jul 25;114(2):181-90 - PubMed
  62. J Immunol. 1992 Nov 15;149(10):3166-73 - PubMed
  63. Oncogene. 2003 Nov 24;22(53):8628-33 - PubMed
  64. Oncogene. 2003 Dec 8;22(56):9030-40 - PubMed
  65. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3438-43 - PubMed
  66. Biochem J. 2004 Sep 1;382(Pt 2):651-7 - PubMed
  67. Science. 2004 Sep 3;305(5689):1471-4 - PubMed
  68. J Biol Chem. 2005 Apr 22;280(16):15709-18 - PubMed
  69. Cancer Biol Ther. 2005 Apr;4(4):393-7 - PubMed
  70. Cell Death Differ. 2005 Jul;12(7):773-82 - PubMed
  71. Lab Invest. 2005 Jul;85(7):885-94 - PubMed
  72. Genes Dev. 2005 Jun 1;19(11):1294-305 - PubMed
  73. BMC Cancer. 2005 May 25;5:54 - PubMed
  74. Neoplasia. 2005 Jun;7(6):594-602 - PubMed
  75. Acta Pharmacol Sin. 2005 Nov;26(11):1373-81 - PubMed
  76. J Biol Chem. 2005 Dec 9;280(49):40599-608 - PubMed
  77. Cancer Res. 2005 Dec 15;65(24):11265-70 - PubMed
  78. Mol Cell. 2005 Dec 22;20(6):939-49 - PubMed
  79. J Biol Chem. 2006 May 19;281(20):13964-71 - PubMed
  80. Clin Cancer Res. 2006 Apr 15;12(8):2640-6 - PubMed
  81. Nature. 2006 May 25;441(7092):437-43 - PubMed
  82. Oncogene. 2006 Nov 30;25(56):7434-9 - PubMed
  83. Autophagy. 2005 Apr;1(1):46-52 - PubMed
  84. Mol Cell Biol. 2006 Oct;26(19):7046-55 - PubMed
  85. Mol Cancer Ther. 2006 Sep;5(9):2251-60 - PubMed
  86. Sci STKE. 2006 Oct 17;2006(357):re13 - PubMed
  87. Annu Rev Nutr. 2007;27:19-40 - PubMed
  88. Nat Rev Mol Cell Biol. 2007 May;8(5):405-13 - PubMed
  89. Int J Biochem Cell Biol. 2007;39(7-8):1462-75 - PubMed
  90. Cancer Cell. 2007 Jul;12(1):66-80 - PubMed
  91. Nat Rev Mol Cell Biol. 2007 Nov;8(11):931-7 - PubMed
  92. Nat Med. 2007 Sep;13(9):1070-7 - PubMed
  93. Oncol Rep. 2007 Nov;18(5):1239-42 - PubMed
  94. Eur J Immunol. 2008 Jan;38(1):54-63 - PubMed
  95. Oncogene. 2008 May 15;27(22):3211-20 - PubMed
  96. Drug Resist Updat. 2008 Feb-Apr;11(1-2):17-24 - PubMed
  97. J Biol Chem. 2008 Jul 11;283(28):19665-77 - PubMed
  98. Cancer Res. 2008 Apr 15;68(8):2944-51 - PubMed
  99. Mol Cell. 2008 Jun 20;30(6):689-700 - PubMed
  100. Cancer Res. 2008 Oct 1;68(19):7956-65 - PubMed
  101. Blood. 2009 Feb 19;113(8):1710-22 - PubMed
  102. Apoptosis. 2009 Apr;14(4):607-23 - PubMed
  103. EMBO J. 2009 Mar 18;28(6):677-85 - PubMed
  104. Tohoku J Exp Med. 2009 Mar;217(3):203-8 - PubMed
  105. Cell. 2009 Mar 20;136(6):1098-109 - PubMed
  106. Nat Rev Cancer. 2009 May;9(5):361-71 - PubMed
  107. Nature. 2009 May 21;459(7245):428-32 - PubMed
  108. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8169-74 - PubMed
  109. Cell Res. 2009 Jun;19(6):758-67 - PubMed
  110. Nature. 2009 Aug 20;460(7258):1035-9 - PubMed
  111. Placenta. 2009 Oct;30(10):855-60 - PubMed
  112. Curr Opin Cell Biol. 2009 Dec;21(6):871-7 - PubMed
  113. Mol Cell. 2009 Nov 25;36(4):696-703 - PubMed
  114. Cancer Biol Ther. 2010 Apr 15;9(8):618-31 - PubMed
  115. J Clin Oncol. 2010 Mar 20;28(9):1527-33 - PubMed
  116. Cancer Biother Radiopharm. 2010 Feb;25(1):13-9 - PubMed
  117. J Mol Med (Berl). 2010 Jul;88(7):729-40 - PubMed
  118. J Clin Oncol. 2010 Jun 10;28(17):2839-46 - PubMed
  119. Curr Opin Investig Drugs. 2010 Jun;11(6):688-98 - PubMed
  120. J Immunol. 2010 Jul 1;185(1):532-41 - PubMed
  121. J Cell Biol. 2010 Aug 9;190(3):377-89 - PubMed
  122. Clin Cancer Res. 2010 Dec 1;16(23):5734-49 - PubMed
  123. Science. 2010 Dec 3;330(6009):1344-8 - PubMed
  124. Cancer Cell. 2011 Jan 18;19(1):101-13 - PubMed
  125. Cell Death Dis. 2010 Aug 26;1:e68 - PubMed
  126. Nature. 2011 Mar 17;471(7338):363-7 - PubMed
  127. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  128. Clin Cancer Res. 2011 May 15;17(10):3181-92 - PubMed
  129. Pathol Oncol Res. 2011 Sep;17(3):729-34 - PubMed
  130. Clin Med Insights Oncol. 2011;5:131-44 - PubMed
  131. Cancer Lett. 2013 May 28;332(2):184-93 - PubMed
  132. Nat Cell Biol. 2011 Sep 02;13(9):1016-23 - PubMed
  133. Br J Cancer. 2011 Oct 25;105(9):1322-30 - PubMed
  134. Genes Dev. 2011 Oct 1;25(19):1999-2010 - PubMed
  135. J Clin Oncol. 2011 Nov 20;29(33):4442-51 - PubMed
  136. Br J Cancer. 2011 Dec 6;105(12):1830-8 - PubMed
  137. Mol Cell. 2011 Nov 18;44(4):517-31 - PubMed
  138. Oncotarget. 2011 Oct;2(10):739-51 - PubMed
  139. Cancer Chemother Pharmacol. 2012 Mar;69(3):799-805 - PubMed
  140. Exp Cell Res. 2012 Jul 1;318(11):1324-31 - PubMed
  141. Mol Cancer Ther. 2012 Jul;11(7):1518-27 - PubMed
  142. Oncogene. 2013 Mar 14;32(11):1341-50 - PubMed
  143. Cell Rep. 2012 May 31;1(5):401-7 - PubMed
  144. Mol Cell. 2012 Jul 27;47(2):291-305 - PubMed
  145. Aging (Albany NY). 2012 May;4(5):330-49 - PubMed
  146. J Cell Sci. 2012 Oct 1;125(Pt 19):4651-61 - PubMed
  147. Autophagy. 2012 Dec;8(12):1811-21 - PubMed
  148. J Clin Oncol. 2012 Nov 20;30(33):4141-7 - PubMed
  149. Cell Death Dis. 2012 Oct 25;3:e414 - PubMed
  150. Methods Mol Biol. 2013;947:575-86 - PubMed
  151. Cold Spring Harb Perspect Biol. 2013 Feb 01;5(2):null - PubMed
  152. Cell Death Dis. 2013 Mar 07;4:e522 - PubMed
  153. Invest New Drugs. 2014 Feb;32(1):135-44 - PubMed
  154. Br J Pharmacol. 2013 Aug;169(8):1723-44 - PubMed
  155. Cell Death Dis. 2013 Jul 04;4:e702 - PubMed
  156. Oncotarget. 2013 Sep;4(9):1349-64 - PubMed
  157. Clin Colorectal Cancer. 2013 Dec;12(4):248-54 - PubMed
  158. Mol Cancer Ther. 2013 Dec;12(12):2735-47 - PubMed
  159. Gastroenterology. 2014 Jan;146(1):278-90 - PubMed
  160. Cancer. 2013 Dec 15;119(24):4290-8 - PubMed
  161. Nat Commun. 2013;4:2799 - PubMed
  162. Clin Cancer Res. 2014 Jan 15;20(2):289-95 - PubMed
  163. J Biol Chem. 2014 Mar 7;289(10):6485-97 - PubMed
  164. Cell Death Differ. 2014 Mar;21(3):491-502 - PubMed
  165. Nat Rev Mol Cell Biol. 2014 Feb;15(2):81-94 - PubMed
  166. Cancer Med. 2013 Dec;2(6):925-32 - PubMed
  167. Cytokine Growth Factor Rev. 2014 Apr;25(2):185-93 - PubMed
  168. Mol Cancer Ther. 2014 Mar;13(3):643-50 - PubMed
  169. Cell Rep. 2014 Apr 10;7(1):45-52 - PubMed
  170. Recent Results Cancer Res. 2014;201:325-45 - PubMed
  171. J Biol Chem. 2014 Jun 6;289(23):16576-87 - PubMed
  172. Int J Cancer. 2015 Oct 15;137(8):1791-9 - PubMed
  173. Oncogene. 2015 Apr 16;34(16):2138-2144 - PubMed
  174. Biochem Biophys Res Commun. 2014 Jul 18;450(1):267-73 - PubMed
  175. Cell Death Differ. 2014 Sep;21(9):1350-64 - PubMed
  176. J Clin Pharm Ther. 2014 Dec;39(6):680-4 - PubMed
  177. Am J Hematol. 2014 Nov;89(11):1037-42 - PubMed
  178. Cell Death Dis. 2014 Aug 28;5:e1390 - PubMed
  179. Cell Death Dis. 2014 Oct 09;5:e1444 - PubMed
  180. PLoS One. 2014 Oct 13;9(10):e109756 - PubMed
  181. Mol Med Rep. 2015 Jan;11(1):203-11 - PubMed
  182. Cell Death Dis. 2014 Nov 06;5:e1510 - PubMed
  183. MAbs. 2014;6(6):1560-70 - PubMed
  184. Cancer Chemother Pharmacol. 2015 May;75(5):887-95 - PubMed
  185. Transl Lung Cancer Res. 2012 Jun;1(2):158-9 - PubMed
  186. Cancer Cell. 2015 Apr 13;27(4):561-73 - PubMed
  187. Cell Death Differ. 2015 Jul;22(7):1071-80 - PubMed
  188. Mol Syst Biol. 2015 May 07;11(5):803 - PubMed
  189. Oncogene. 2016 Mar 10;35(10):1261-70 - PubMed
  190. Mol Cell Biol. 2015 Oct;35(19):3324-38 - PubMed
  191. Cancer Chemother Pharmacol. 2015 Nov;76(5):1025-32 - PubMed
  192. Cell Death Differ. 2016 Apr;23(4):681-94 - PubMed
  193. Oncotarget. 2015 Dec 8;6(39):41902-15 - PubMed
  194. Cancer. 2016 Feb 15;122(4):588-597 - PubMed
  195. Lancet Haematol. 2015 Apr;2(4):e166-74 - PubMed
  196. Cancer Lett. 2017 Feb 28;387:61-68 - PubMed
  197. Cell Death Differ. 2016 May;23(5):733-47 - PubMed
  198. Mol Cell. 2016 Mar 17;61(6):834-49 - PubMed
  199. Mol Cancer Ther. 2016 May;15(5):946-57 - PubMed
  200. Cold Spring Harb Perspect Med. 2016 Apr 01;6(4):a026120 - PubMed
  201. J Biol Chem. 2016 May 27;291(22):11843-51 - PubMed
  202. Oncotarget. 2016 Jul 5;7(27):41488-41504 - PubMed
  203. Lancet Oncol. 2016 Jun;17(6):768-778 - PubMed
  204. Dev Cell. 2016 May 23;37(4):291-293 - PubMed
  205. Oncogene. 2017 Jan 26;36(4):458-470 - PubMed
  206. EBioMedicine. 2016 Jun;8:40-48 - PubMed
  207. Chin J Cancer. 2016 Sep 08;35(1):86 - PubMed
  208. Cancer Lett. 2017 Mar 28;389:70-77 - PubMed
  209. Cancer Cell. 2017 Jan 9;31(1):142-156 - PubMed
  210. J Cell Commun Signal. 2017 Sep;11(3):219-226 - PubMed
  211. Cell Death Differ. 2017 Mar;24(3):500-510 - PubMed
  212. Autophagy. 2008 Jul 1;4(5):600-606 - PubMed
  213. Mol Cell. 2017 Feb 16;65(4):730-742.e5 - PubMed
  214. Int Rev Cell Mol Biol. 2017;330:157-169 - PubMed
  215. EMBO J. 2017 May 2;36(9):1147-1166 - PubMed
  216. Biomed Pharmacother. 2017 Jun;90:24-37 - PubMed
  217. Cancer Chemother Pharmacol. 2017 Jun;79(6):1141-1149 - PubMed
  218. Nat Rev Cancer. 2017 May 24;17(6):352-366 - PubMed
  219. EMBO J. 2017 Jul 3;36(13):1811-1836 - PubMed
  220. Sci Rep. 2017 Jul 17;7(1):5514 - PubMed
  221. Exp Cell Res. 2017 Nov 15;360(2):226-235 - PubMed
  222. Cell Oncol (Dordr). 2017 Dec;40(6):593-607 - PubMed
  223. Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316 - PubMed
  224. Blood. 2017 Nov 30;130(22):2401-2409 - PubMed
  225. Cell Death Differ. 2018 Jan;25(1):46-55 - PubMed
  226. Invest New Drugs. 2018 Apr;36(2):315-322 - PubMed
  227. Trends Cancer. 2017 Dec;3(12):857-870 - PubMed
  228. Lancet Oncol. 2018 Jan;19(1):65-75 - PubMed
  229. Int J Mol Sci. 2018 Mar 02;19(3):null - PubMed
  230. Biomolecules. 2018 Mar 21;8(2): - PubMed
  231. Cancers (Basel). 2018 Mar 18;10(3):null - PubMed
  232. Cell Death Dis. 2018 Apr 18;9(5):445 - PubMed
  233. Sci Rep. 2018 Nov 30;8(1):17519 - PubMed
  234. Cell Death Differ. 2019 Mar;26(4):605-616 - PubMed
  235. Cancers (Basel). 2019 Jan 15;11(1):null - PubMed
  236. Cell Death Dis. 2019 Feb 17;10(3):247 - PubMed
  237. Br J Cancer. 1972 Aug;26(4):239-57 - PubMed
  238. FEBS Lett. 1993 Oct 25;333(1-2):169-74 - PubMed
  239. EMBO J. 1996 Jun 3;15(11):2685-94 - PubMed
  240. J Biol Chem. 1996 May 31;271(22):12687-90 - PubMed
  241. Immunity. 1995 Dec;3(6):673-82 - PubMed
  242. Science. 1997 Apr 4;276(5309):111-3 - PubMed
  243. Cell. 1997 Apr 18;89(2):309-19 - PubMed
  244. Nature. 1997 Jul 10;388(6638):190-5 - PubMed
  245. Science. 1997 Aug 8;277(5327):815-8 - PubMed
  246. Science. 1997 Aug 8;277(5327):818-21 - PubMed
  247. EMBO J. 1997 Sep 1;16(17):5386-97 - PubMed
  248. Curr Biol. 1997 Dec 1;7(12):1003-6 - PubMed
  249. Immunity. 1997 Dec;7(6):813-20 - PubMed
  250. Immunity. 1997 Dec;7(6):821-30 - PubMed
  251. Immunity. 1997 Dec;7(6):831-6 - PubMed
  252. EMBO J. 1998 Apr 15;17(8):2215-23 - PubMed
  253. J Biol Chem. 1998 Jun 5;273(23):14363-7 - PubMed
  254. Cell. 1998 Aug 21;94(4):481-90 - PubMed
  255. J Biol Chem. 1999 Jan 15;274(3):1541-8 - PubMed
  256. Nat Med. 1999 Feb;5(2):157-63 - PubMed

Publication Types